All lobbying filings

Venn Strategies

Venn Strategies filed a Q3 report for Eli Lilly and Company on October 20, 2026, reporting $50,000 in lobbying income.

Lobbying for Eli Lilly and Company · Pharmaceutical company

As filed: VENN STRATEGIES for ELI LILLY AND COMPANY.

All filings by Venn Strategies · Everything Eli Lilly and Company has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Income

$50,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Health Issues

General Healthcare issues, including drug accessibility, importation and innovation policies.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.